In this study, we showed that QSOX2, a secreted protein, was aberrantly expressed in NSCLC and periodically expressed in the cell cycle process of tumor cells, which implied that this protein might be a promising serum marker for the evaluation of tumor suppression after anticancer therapy. This evidence concerns the gene QSOX2 and neoplasm.